E. coli Outbreak in Canada
Provides Study Opportunity for Company
CALGARY, CANADA-An outbreak of E. coli has provided an unique opportunity for a pharmaceutical company developing a drug to treat the bacteria. Canadian-based Synsorb Biotech was asked to supply its Synsorb Pk(R) to hospitals in Walkerton, Ontario, where hundreds of residents have become ill after drinking contaminated water. The Canadian Health Authorities issued approval for emergency use of the treatment designed to prevent serious complications associated with verotoxigenic E. coli (VTEC) infections. Synsorb Pk(R) attaches to the bacteria's toxins and neutralizes them allowing safe passage through the digestive tract. According to Synsorb, approximately 10% of the patients who become infected with E. coli develop Hemolytic Uremic Syndrome (HUS), a potentially deadly kidney disease. Consequently, the treatment has been given fast track product designation by the US Food and Drug Administration (FDA). Synsorb has been delayed producing clinical trial results because large-scale outbreaks are rare.
The CDC at a Crossroads: Budget Cuts, Public Health, and the Growing Threat of Infectious Diseases
March 12th 2025Budget cuts to the CDC threaten disease surveillance, outbreak response, and public health programs, increasing risks from measles, avian flu, and future pandemics while straining health care infrastructure nationwide.
Standing Up for Science: A Rally Participant’s Perspective
March 11th 2025Infection Control Today's Editorial Advisory Board member and contributing editor, Heather Stoltzfus, MPH, RN, CIC, recently joined the Stand Up for Science rally in Washington, DC. She gives a first-person perspective on the rally and the rally-goers' strong message.
